Published in Managed Care Law Weekly, August 6th, 2006
Researchers in England conducted a study "to present an economic model and cost-effectiveness estimates for lamotrigine in maintenance treatment of bipolar I disorder (BD-I) using outcomes from the pivotal lamotrigine trials."
"The main comparator treatments in the pivotal trials were lithium and 'no maintenance' (acute-only) treatment. A comparison with olanzapine was included as an indirect analysis following publication of data during the course of our research. A Markov model was built around the three health states of euthymia, mania, and depression,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.